Galera Therapeutics Files 8-K: Material Agreements and Shareholder Rights
Ticker: GRTX · Form: 8-K · Filed: May 3, 2024 · CIK: 1563577
Sentiment: neutral
Topics: material-agreement, security-holder-rights, corporate-action
TL;DR
Galera Therapeutics filed an 8-K detailing material agreements and changes affecting security holders.
AI Summary
On May 2, 2024, Galera Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in this 8-K filing. The filing also addresses material modifications to the rights of security holders and amendments to the company's governing documents. This report is filed under Regulation FD, ensuring public disclosure of material information.
Why It Matters
This filing indicates significant corporate actions by Galera Therapeutics, potentially impacting its business operations, financial structure, and shareholder value.
Risk Assessment
Risk Level: medium — The filing concerns material definitive agreements and modifications to security holder rights, which can introduce significant business and financial risks.
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- May 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 45 Liberty Blvd #230 Malvern, PA 19355 (address) — Principal executive offices
FAQ
What specific material definitive agreement was entered into by Galera Therapeutics?
The filing indicates the entry into a Material Definitive Agreement, but the specific details of this agreement are not provided in the provided text excerpt.
What are the key modifications to the rights of Galera Therapeutics' security holders?
The filing states there were material modifications to the rights of security holders, but the specific nature of these modifications is not detailed in the provided text.
Are there any amendments to Galera Therapeutics' articles of incorporation or bylaws?
Yes, the filing indicates amendments to the company's articles of incorporation or bylaws, though the specifics are not detailed in the excerpt.
What is the significance of the Regulation FD Disclosure item in this filing?
The Regulation FD Disclosure item signifies that the company is making public disclosures of material information that could affect investors, ensuring fair and widespread dissemination.
When was Galera Therapeutics incorporated and in which state?
Galera Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 2,930 words · 12 min read · ~10 pages · Grade level 14.3 · Accepted 2024-05-03 16:24:58
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX The Nasdaq
- $1.50 — of the Company at an exercise price of $1.50 per Right, subject to adjustment. The d
- $1,000 — vidend payments equal to the greater of $1,000 per share and 1,000 times the amount of
Filing Documents
- d835891d8k.htm (8-K) — 57KB
- d835891dex991.htm (EX-99.1) — 8KB
- g835891image001.jpg (GRAPHIC) — 2KB
- 0001193125-24-130779.txt ( ) — 201KB
- grtx-20240502.xsd (EX-101.SCH) — 3KB
- grtx-20240502_lab.xml (EX-101.LAB) — 18KB
- grtx-20240502_pre.xml (EX-101.PRE) — 11KB
- d835891d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 3.1 Certificate of Designation of the Series A Junior Participating Preferred Stock of the Company, dated May 3, 2024 (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on May 3, 2024, File No. 001-39114) 4.1 Stockholder Rights Agreement, dated as of May 3, 2024, by and between the Company and Equiniti Trust, LLC, as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto) (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on May 3, 2024, File No. 001-39114) 99.1 Press Release issued by the Company on May 3, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document) 7
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: May 3, 2024 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer